OBJECTIVE: To assess the risk of @entity281 in @entity1 with @entity1252 ( @entity1252 ) treated with plasmapheresis in addition to intravenous (I.V.) pulse @entity786 (CYC). METHODS: We searched the records of all our @entity1252 @entity1 for those who had undergone plasmapheresis plus I.V. CYC treatment (n = 9). Consecutive @entity1 with similarly high @entity1252 activity who underwent I.V. CYC therapy but not plasmapheresis were included as controls (n = 12). We evaluated both groups for severe @entity281 , outcome, and confounding clinical variables. RESULTS: Seven of 9 plasmapheresis-treated @entity1 had serious @entity2348 , including 3 cases of @entity2803 . Among the 12 @entity1 treated with I.V. CYC alone, only 2 had severe @entity281 (P < 0.01). Three @entity1 in the plasmapheresis group and none in the control group died of @entity281 . Treatment efficacy, however, was similar for both groups. CONCLUSION: Among @entity1252 @entity1 treated with plasmapheresis and I.V. CYC, life-threatening @entity2348 and mortality occur more frequently than among @entity1 with similarly active @entity1252 treated with I.V. CYC alone.

Severe XXXX in plasmapheresis-treated @entity1252 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2803 :: ('MESH:D003586', 'Disease') :: ['cytomegalovirus infections'] @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial or viral infections', 'bacterial and viral infections'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']
@entity281 :: (MESH:D007239,Disease) :: ['infections']
